Eli Lilly's obesity drug Mounjaro will be available through Britain's state health system for some patients from March, after ...

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Eli Lilly just gave investors several reasons to cheer.

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

FDA has ordered specialty pharmacies and online companies to phase out knockoff versions of Eli Lilly's blockbuster drugs ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.93% and ...

Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online ...

Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...